BMI View: The launch of the universal healthcare system in Indonesia is generally positive for
pharmaceutical firms, particularly domestic firms that commercialise generic drugs.
We maintain that the rollout of the scheme will be challenging, given logistical and huma ..."
BMI View: Local newspaper The Jakarta Post recently reported that Indonesia plans to reduce the foreign
ownership cap in various sectors, such as pharmaceuticals, ecotourism and telecommunication in order to
boost foreign direct investment (FDI) in the country. It is ..."
? BMI View: We are broadly maintaining our forecasts for the Indonesian pharmaceutical market, the
growth of which will be supported by the government's quest for better healthcare provision and the
industry's desire to capitalise on these healthcare initiatives. Howe ..."
BMI View: Theoretically, considerable opportunities for pharmaceutical manufacturers exist in relation to
the Indonesian pharmaceutical market. Demand for medicines will continue to be supported by the
country's large population, the rollout of the universal healthcare programm ..."
BMI View: Commercial interest in Indonesia's healthcare sector will accelerate over the course of 2014, the year that marks the introduction of universal health insurance. The programme is expected to offer numerous opportunities for drugmakers, medical device manufacturers and p ..."
Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor governance in several countries ..."
Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor ..."